Physician profile
Peter J Koerner
NPI 1922349836
$11,161.95
in general payments reported to CMS, 2019-2025
31 companies · $2,218 in 2025
The $2,218 reported for 2025 was more than what 97% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $534 · 2020: $758 · 2021: $1,228 · 2022: $2,612 · 2023: $1,653 · 2024: $2,159 · 2025: $2,218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,969 · Entertainment: $60.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,968.91 |
| Entertainment | $60.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,671.46 | 2019-2025 | Clareon, Total30, Rocklatan |
| Sun Pharmaceutical Industries INC. | $1,464.12 | 2020-2025 | Cequa, Xelpros |
| Bausch & Lomb Americas INC. | $849.04 | 2022-2025 | Vyzulta, Miebo, Biotrue One Day |
| Abbvie INC. | $698.42 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $607.57 | 2021-2023 | |
| Tarsus Pharmaceuticals, INC. | $581.79 | 2024-2025 | Xdemvy |
| Biotissue Holdings INC. | $539.30 | 2022-2025 | |
| Allergan, INC. | $466.99 | 2020-2022 | |
| Sight Sciences, INC. | $438.63 | 2022-2025 | Omni Surgical System, Tearcare System |
| Mallinckrodt Hospital Products INC. | $391.85 | 2020-2024 | Acthar |
| Glaukos Corporation | $358.03 | 2021-2025 | Idosetr, Idose, Istent Infinite |
| Oyster Point Pharma, INC. | $325.64 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Kala Pharmaceuticals, INC. | $310.75 | 2020-2022 | |
| Coopervision INC. | $309.13 | 2019-2025 | Misight Contact Lens, Myday Contact Lens |
| Horizon Therapeutics Plc | $299.06 | 2021-2023 | Tepezza |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $243.70 | 2019-2022 | |
| New World Medical,INC. | $227.93 | 2024-2025 | Clearpath, Streamline, Ahmed Glaucoma Valve |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $204.13 | 2019-2021 | |
| Harrow Eye, LLC | $165.78 | 2024-2025 | Vevye, Iheezo |
| Johnson & Johnson Surgical Vision, INC. | $138.58 | 2021-2022 | |
| Amgen INC. | $132.94 | 2024-2025 | Tepezza |
| Dompe US, INC. | $127.67 | 2021-2025 | Oxervate |
| Thea Pharma INC. | $126.17 | 2023-2024 | Iyuzeh |
| Shire North American Group INC | $124.30 | 2019 | |
| Rayner Intraocular Lenses Limited | $117.73 | 2023-2025 | Rayone Aspheric, Rayone Emv, Rayone Spheric |
| Lkc Technologies, INC. | $88.25 | 2025 | |
| Optos, INC. | $60.17 | 2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Eyevance Pharmaceuticals LLC | $49.14 | 2022-2023 | Flarex |
| Genentech USA, INC. | $15.71 | 2021 | |
| Maculogix, INC. | $14.22 | 2020 | |
| Apellis Pharmaceuticals, INC. | $13.75 | 2025 | Syfovre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Koerner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.